MedTrace Logo

Genetic Studies in Liver Cancer Patients

NCT00172640 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2005-09-15

No results posted yet for this study

Summary

Hepatocellular carcinoma (HCC) is one the most common malignancies in the world, especially in sub-Saharan Africa and Southeast Asia. Since 1984, it has been the leading cause of cancer death in Taiwan. About 6000-8000 people died of this cancer every year in Taiwan. DNA microarray (DNA chip) is a very powerful tool to clarify the genetic changes in cancers. Expression profiling techniques have been used to simultaneously monitor the expression of thousands of genes from human tumor samples. It has been successfully used to predict clinical outcome and survival as well as classify different types of cancer. In this study, we will use the DNA chip to study the genetics in liver cancer patients.

Conditions

Sponsors & Collaborators

  • Industrial Technology Research Institute, Taiwan

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Chien-Hung Chen, MD · National Taiwan University Hospital

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00172640 on ClinicalTrials.gov